Notice of Proposed Sale · 144
Attovia Therapeutics, Inc.
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Attovia Therapeutics, Inc.
- Issuer CIK
- 0002058707
- SEC file number
- 001-43423
- Phone
- 5103995001
- Person for whose account securities are to be sold
- GOLDMAN SACHS GROUP INC
- Relationships to issuer
- Former 10% Owner
- Street
- 1091 INDUSTRIAL ROAD
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 105,807 | 2,221,947.00 | 43,029,017 | 08/05/2026 | See Remarks (1) | Goldman Sachs & Co. LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Goldman Sachs & Co. LLC
- Street
- 200 West Street
- City
- New York
- State / country code
- NY
- Postal code
- 10282
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 08/05/2026 | See Remarks (2) | See Remarks (2) | 105,807 | N | 08/05/2026 | N/A |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
(1) CBOE, IEX, MEMX and Nasdaq. (2) Shares sold were acquired through securities borrowing by Goldman Sachs & Co. LLC acting as a market maker in the ordinary course of business.
Notice signature
- Notice date
- 08/28/2026
- Signed
- /s/ Crystal Orgill, Attorney-in-fact
Company context
We are a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. Our lead pipeline candidates target commercially validated pathways and are designed through our ATTOBODY biologics platform to deliver improved treatments relative to the current standards of care. Leveraging our ATTOBODY platform, we have nominated three product candidates within our first two years, including one currently in the clinic, ATTO-1310. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31 (IL-31) that completed dosing in a Phase 1 clinical trial in healthy volunteers (HVs) and patients in the first quarter of 2026. ATTO-2306 is an ATTOBODY-based bispecific targeting interleukin-13 (IL-13) and IL-31 that is in investigational new drug (IND)-enabling studies, and we expect to commence a Phase 1 clinical trial in the first half of 2027. Lastly, ATTO-1091 is our trispecific ATTOBODY-based Fc fusion protein that is designed to block TL1A, IL-23 and integrin a4ß7 simultaneously, and is currently in IND-enabling studies.